title: Resistance to amoxicillin, clarithromycin and ciprofloxacin of Helicobacter pylori isolated from Southern Brazil patients.
abstract: BACKGROUND
  Helicobacter pylori is a bacteria which infects half the world population and is an important cause of gastric cancer. The eradication therapy is not always effective because resistance to antimicrobials may occur. The aim of this study was to determine the susceptibility profile of H. pylori to amoxicillin, clarithromycin and ciprofloxacin in the population of Southern Brazil.
  
  
  METHODS
  Fifty four samples of H. pylori were evaluated. The antibiotics susceptibility was determined according to the guidelines of the British Society for Antimicrobial Chemotherapy and the Comité de l'Antibiogramme de la Société Française de Microbiologie.
  
  
  RESULTS
  Six (11.1%) H. pylori isolates were resistant to clarithromycin, one (1.9%) to amoxicillin and three (5.5%) to ciprofloxacin. These indices of resistance are considered satisfactory and show that all of these antibiotics can be used in the empirical therapy.
  
  
  CONCLUSIONS
  The antibiotics amoxicillin and clarithromycin are still a good option for first line anti-H. pylori treatment in the population of Southern Brazil.
authors.affiliation: Institute of Health Sciences, Universidade Feevale, Novo Hamburgo, RS, Brazil.
authors.forename: Simone Ulrich
authors.initials: SU
authors.lastname: Picoli
authors.affiliation: School of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
authors.forename: Luiz Edmundo
authors.initials: LE
authors.lastname: Mazzoleni
authors.affiliation: Institute of Clinical Microbiology, School of Medicine, Universidad Austral de Chile, Valdivia, Chile.
authors.forename: Heriberto
authors.initials: H
authors.lastname: Fernández
authors.affiliation: Hospital de Clínicas de Porto Alegre, Service of Gastroenterology, Porto Alegre, RS, Brazil.
authors.forename: Laura Renata
authors.initials: LR
authors.lastname: De Bona
authors.affiliation: Centro Universitário Metodista, Porto Alegre, RS, Brazil.
authors.forename: Erli
authors.initials: E
authors.lastname: Neuhauss
authors.affiliation: Hospital de Clínicas de Porto Alegre, Service of Gastroenterology, Porto Alegre, RS, Brazil.
authors.forename: Larisse
authors.initials: L
authors.lastname: Longo
authors.affiliation: Programa de Pós-Graduação em Gastroenterologia e Hepatologia, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
authors.forename: João Carlos
authors.initials: JC
authors.lastname: Prolla
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000658:Amoxicillin / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology*; D017291:Clarithromycin / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D016481:Helicobacter Infections / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D000658:Amoxicillin; D017291:Clarithromycin